Lisata Therapeutics (LSTA) and Valo Therapeutics announced a preclinical research collaboration to investigate the benefits of combining Lisata’s novel product candidate, certepetide, with ValoTx’s platform technology, PeptiCRAd, and a checkpoint inhibitor in a melanoma mouse model. Under the agreement, ValoTx will be conducting the research, while Lisata will supply certepetide product.